VKTX vs. PRTA, ICPT, PBYI, MRNS, ALNY, GMAB, TEVA, RPRX, BGNE, and BMRN
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Prothena (PRTA), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI), Marinus Pharmaceuticals (MRNS), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), BeiGene (BGNE), and BioMarin Pharmaceutical (BMRN).
Prothena (NASDAQ:PRTA) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.
Prothena has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Prothena currently has a consensus price target of $67.00, suggesting a potential upside of 221.96%. Viking Therapeutics has a consensus price target of $112.38, suggesting a potential upside of 80.49%. Given Viking Therapeutics' higher possible upside, research analysts clearly believe Prothena is more favorable than Viking Therapeutics.
Viking Therapeutics has lower revenue, but higher earnings than Prothena. Viking Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
97.1% of Prothena shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 28.2% of Prothena shares are held by company insiders. Comparatively, 4.7% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Prothena received 1 more outperform votes than Viking Therapeutics when rated by MarketBeat users. However, 79.76% of users gave Viking Therapeutics an outperform vote while only 70.67% of users gave Prothena an outperform vote.
In the previous week, Viking Therapeutics had 1 more articles in the media than Prothena. MarketBeat recorded 11 mentions for Viking Therapeutics and 10 mentions for Prothena. Prothena's average media sentiment score of 0.91 beat Viking Therapeutics' score of 0.80 indicating that Viking Therapeutics is being referred to more favorably in the news media.
Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -193.17%. Prothena's return on equity of -18.41% beat Viking Therapeutics' return on equity.
Summary
Viking Therapeutics beats Prothena on 12 of the 18 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
